MedTrace Logo

Evaluation of the Effect of Pure Canterbury Stage 1 Infant Formula Milk Powder on the Growth of Infant 0-6 Months of Age

NCT02239588 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-09-15

No results posted yet for this study

Summary

This was a randomized, double-blind, single-center, placebo-controlled, three-arm study, with a 12-week intervention period.

The objectives of this study were to evaluate the effect of Pure Canterbury Stage 1 (0-6 months) milk powder on:

1. Bone health;
2. Infants growth;
3. Intestinal health;
4. Gastrointestinal tolerance to the test product;

g) Incidence of Eczema

Conditions

  • Growth Acceleration

Interventions

OTHER

Oral consumption

Daily oral consumption for 12 weeks: Placebo; Pure Canterbury; Other infant formula milk powder: 1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months) 2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months) 3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months) 4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months) 5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months) 6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)

Sponsors & Collaborators

  • Bright Dairy & Food Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaoyang Sheng, MD · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
7 Days
Max Age
90 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02239588 on ClinicalTrials.gov